China SXT Pharmaceuticals, Inc. (SXTC) stock
SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31
$2.86−0.13 (-4.35%)
Close on Nov 17, 2026Market cap $2.74MP/E –Yield –
China SXT Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2026 it was $1.14M, down 34.6% from the year before. The highest annual figure on record is $7.02M in fiscal 2018.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $1.14M | -34.6% |
| FY2025 | Mar 31, 2025 | $1.74M | -9.7% |
| FY2024 | Mar 31, 2024 | $1.93M | -2.2% |
| FY2023 | Mar 31, 2023 | $1.97M | -24.2% |
| FY2022 | Mar 31, 2022 | $2.60M | -45.5% |
| FY2021 | Mar 31, 2021 | $4.78M | -7.5% |
| FY2020 | Mar 31, 2020 | $5.16M | -26.4% |
| FY2019 | Mar 31, 2019 | $7.01M | -0.1% |
| FY2018 | Mar 31, 2018 | $7.02M | +43.8% |
| FY2017 | Mar 31, 2017 | $4.88M | – |
See a number that looks wrong?